Holen Sie sich die Stockscreener-App
98.16
0.75%
-0.74
Handel nachbörslich:
97.98
-0.18
-0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$98.90
Offen:
$97.25
24-Stunden-Volumen:
12.99M
Relative Volume:
1.44
Marktkapitalisierung:
$128.55B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
20.67
EPS:
4.75
Netto-Cashflow:
$10.37B
1W Leistung:
-4.93%
1M Leistung:
-4.87%
6M Leistung:
+1.65%
1J Leistung:
+51.20%
1-Tages-Spanne:
$95.30
$98.44
1-Wochen-Bereich:
$95.30
$105.17
52-Wochen-Spanne:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
98.16 | 128.55B | 28.73B | 5.97B | 10.37B | 4.75 |
|
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences Holds Annual Stockholders Meeting - TipRanks
Gilead Joins Pharma’s US Investment Rush - insights.citeline.com
Gilead Sciences holds annual stockholders meeting - Investing.com
Gilead reports final outcomes from trial of bulevirtide for chronic HDV - Clinical Trials Arena
Drugmaker Gilead pledges $11 billion investment in U.S. manufacturing - The Business Journals
Gilead Sciences Increases Investment in U.S. Operations - Contract Pharma
Earth Day Focus for Gilead SciencesEvery Action Has an Impact - ACCESS Newswire
Gilead ups its US investment plans by $11 billion - Pharmaphorum
Gilead Pumps $11B More Into US Manufacturing, Hopes To Add 3,000 Jobs - BioSpace
Earth Day Focus for Gilead Sciences – Every Action Has an Impact - 3BL Media
Gilead tees up $11B in new US manufacturing, R&D investments - Fierce Pharma
Gilead to invest $32 billion in US manufacturing and R&D - The Pharma Letter
How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock - Yahoo Finance
Gilead announces $11 billion in new investments in US - MSN
Gilead is latest to pledge allegiance to America with $32B manufacturing commitment - FirstWord Pharma
Gilead boosts planned US investments by $11 billion amid tariff threat - MSN
Gilead (GILD) to Boost U.S. Operations with $11 Billion Investment | GILD Stock News - GuruFocus
Gilead Sciences (GILD) Boosts U.S. Investment by $11 Billion - GuruFocus
Gilead Sciences Announces $11 Billion U.S. Investment BoostNews and Statistics - IndexBox
Gilead to invest $32B in U.S. manufacturing through 2030 - Seeking Alpha
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing By Investing.com - Investing.com
Gilead announces $11 billion in new investments in US By Reuters - Investing.com
Gilead Sciences (GILD) U.S. Investment to Create $43B in Value to U.S. Economy - StreetInsider
Gilead Boosts Planned US Investments by $11 Billion Amid Tariff Threat - US News Money
Gilead To Invest $32 Bln In U.S. Manufacturing And R&D Through 2030 - marketscreener.com
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025 - simplywall.st
Fighting the World’s Most Devastating Diseases Is the Focus of This Installment of “The Centrifuge Sessions - CSRwire
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - BioSpace
Gilead (GILD): Livdelzi Shows Promising Results for PBC Treatment | GILD Stock News - GuruFocus
GILD: Promising Results from Gilead's Bulevirtide Study for Chronic Hepatitis Delta | GILD Stock News - GuruFocus
Gilead to Invest $11 Billion to Bolster Domestic Operations - WSJ
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy - GuruFocus
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead (GILD) Sees Bearish Options Activity with Heavy Put Trading | GILD Stock News - GuruFocus
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions" - marketscreener.com
Gilead: Sure, Why Not, But Not The CDRs (GILD:CA) - Seeking Alpha
What Are Wall Street Analysts' Target Price for Gilead Sciences Stock? - Nasdaq
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating - marketscreener.com
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo
What Are Wall Street Analysts' Target Price For Gilead Sciences Stock? - Barchart.com
Gilead (GILD) Sees 24% Stock Surge Amid Tariff Resilience - GuruFocus
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Here's What to Expect From Gilead Sciences’ Next Earnings Report - MSN
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investor - The Business Journals
Gilead Sciences (GILD): A Promising Pick Amid Economic Uncertain - GuruFocus
June 13th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Agrees To Pay $202M To Settle Alleged Speaker Kickback Claims In FCA Suit - Law360
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - MSN
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):